

Marinomed Biotech AG evaluates strategic options for Carragelose portfolio

Conference Call

December 18th, 2023

CEO Andreas Grassauer


CSO Eva Prieschl-Grassauer

CFO Pascal Schmidt



Core: Research & development and generation of IP

At the center of Marinomed's business model



Carragelose business unit

Premium-quality medical device portfolio: from an idea to marketed products


Carragelose business

- B2B white label business model
- Active licensing contracts with multiple international companies
- Outsourced production, regulatory, and marketing & distribution
- Broad clinical and pre-clinical data for products' claims and marketing
- Products sold in more than 40 countries
- Products clearly differentiated from competition
- Untapped growth potential through ongoing licensing negotiations and readily developed new products

Product portfolio marketed products




Carragelose revenues



Marinomed developed Carragelose to a self-sustaining business – ready to be taken to the next level

Carragelose is MDR-ready

MDR transition creates favorable environment for Carragelose products




MDR requirements already accomplished by end of 2023	
Process validation 3 batches completed	✓
Stability data 3 batches in time	✓
Clinical data to substantiate the claims completed in time	✓
Biocompatibility data available	✓
Extractable / Leachables data available	✓
MDR compliant documentation available	✓

Marinomed took measures in time to guarantee smooth transition into MDR
Corporates seek to license/acquire MDR-ready assets meeting also requirements for authorization outside EU

Evaluating strategic options for Carragelose business

Maximize value



Higher value for a potential partner means higher value for Marinomed and its stakeholders



Marinomed's platforms & therapeutic areas

Increasing attention to assets that have significant revenue potential

Carragelose®

Universal **blocking of viruses and allergens** as well as moistening of mucosal tissues

Cough & cold portfolio
Viral respiratory infections



Allergy nasal spray
Mild allergic rhinitis



Eye drops
Dry, irritated eyes




Marinosolv®

Solubilization of poorly water-soluble compounds and improving **local onset of action**

Budesolv
Allergic rhinitis



Tacrosolv
Inflammatory eye diseases



Solv4U Technology partnerships



VIROLOGY

IMMUNOLOGY

SOLV4U

Reduce focus

Increase focus



Near term targets and plan for 2024

Sustainable profitability planned starting in 2024

Carragelose® OTC business

- US approval with potential launch by Procter & Gamble in the 2024/25 season
- New partnerships including for allergy and eye care products
- Evaluate strategic options for Carragelose business unit

Commercialization of Marinosolv® key assets

- Partnerships for Budesolv in Europe and the US
- Deals from Tacrosolv partnering process

Finance and General Corporate

- Restructure repayment of EIB loan tranches → deferral of capital repayments

www.marinomed.com

Contact

IR: *Stephanie Kniep, ir@marinomed.com*

PR: *Lucia Ziegler, pr@marinomed.com*

International: *Metrum Communications, Roland Mayrl,
marinomed@metrum.at*

